List of Zegalogue drug patents

Zegalogue is owned by Zealand Pharma.

Zegalogue contains Dasiglucagon Hydrochloride.

Zegalogue has a total of 1 drug patent out of which 0 drug patents have expired.

Zegalogue was authorised for market use on 22 March, 2021.

Zegalogue is available in solution;subcutaneous dosage forms.

Drug patent challenges can be filed against Zegalogue from March, 2025.

The generics of Zegalogue are possible to be released after 03 February, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10442847 ZEALAND PHARMA Glucagon analogues
Feb, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 22, 2026

Drugs and Companies using DASIGLUCAGON HYDROCHLORIDE ingredient

NCE-1 date: March, 2025

Market Authorisation Date: 22 March, 2021

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in